MYC Rules: Leading Glutamine Metabolism Toward a Distinct Cancer Cell Phenotype

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Sep 10

PMID 34503295

Citations 30

Authors

Vincent Tambay

Valerie-Ann Raymond

Marc Bilodeau

Affiliations

Soon will be listed here.

Abstract

Metabolic reprogramming and deregulated cellular energetics are hallmarks of cancer. The aberrant metabolism of cancer cells is thought to be the product of differential oncogene activation and tumor suppressor gene inactivation. MYC is one of the most important oncogenic drivers, its activation being reported in a variety of cancer types and sub-types, among which are the most prevalent and aggressive of all malignancies. This review aims to offer a comprehensive overview and highlight the importance of the c-Myc transcription factor on the regulation of metabolic pathways, in particular that of glutamine and glutaminolysis. Glutamine can be extensively metabolized into a variety of substrates and be integrated in a complex metabolic network inside the cell, from energy metabolism to nucleotide and non-essential amino acid synthesis. Together, understanding metabolic reprogramming and its underlying genetic makeup, such as MYC activation, allows for a better understanding of the cancer cell phenotype and thus of the potential vulnerabilities of cancers from a metabolic standpoint.

Citing Articles

Infectious Spleen and Kidney Necrosis Virus ORF093R and ORF102R Regulate Glutamate Metabolic Reprogramming to Support Virus Proliferation by Interacting with c-Myc.

Niu Y, Ye C, Lin Q, Liang H, Luo X, Ma B Int J Mol Sci. 2025; 26(2).

PMID: 39859431 PMC: 11766233. DOI: 10.3390/ijms26020718.

The interplay of EBV virus and cell metabolism in lung cancer.

Wang H J Cell Mol Med. 2024; 28(22):e70088.

PMID: 39601114 PMC: 11599874. DOI: 10.1111/jcmm.70088.

Establishment and Characterization of Three Human Ocular Adnexal Sebaceous Carcinoma Cell Lines.

Lee S, Peterson C, Wang K, Alaali L, Eshleman J, Mahoney N Int J Mol Sci. 2024; 25(18).

PMID: 39337668 PMC: 11432008. DOI: 10.3390/ijms251810183.

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.

Casacuberta-Serra S, Gonzalez-Larreategui I, Capitan-Leo D, Soucek L Signal Transduct Target Ther. 2024; 9(1):205.

PMID: 39164274 PMC: 11336233. DOI: 10.1038/s41392-024-01907-z.

Reprogramming of Glutamine Amino Acid Transporters Expression and Prognostic Significance in Hepatocellular Carcinoma.

Tambay V, Raymond V, Voisin L, Meloche S, Bilodeau M Int J Mol Sci. 2024; 25(14).

PMID: 39062801 PMC: 11277143. DOI: 10.3390/ijms25147558.

References

Kleszcz R, Paluszczak J, Krajka-Kuzniak V, Baer-Dubowska W . The inhibition of c-MYC transcription factor modulates the expression of glycolytic and glutaminolytic enzymes in FaDu hypopharyngeal carcinoma cells. Adv Clin Exp Med. 2018; 27(6):735-742. DOI: 10.17219/acem/68979. View

Bialopiotrowicz E, Noyszewska-Kania M, Kachamakova-Trojanowska N, Loboda A, Cybulska M, Grochowska A . Serine Biosynthesis Pathway Supports MYC-miR-494-EZH2 Feed-Forward Circuit Necessary to Maintain Metabolic and Epigenetic Reprogramming of Burkitt Lymphoma Cells. Cancers (Basel). 2020; 12(3). PMC: 7139810. DOI: 10.3390/cancers12030580. View

Saborowski M, Saborowski A, Morris 4th J, Bosbach B, Dow L, Pelletier J . A modular and flexible ESC-based mouse model of pancreatic cancer. Genes Dev. 2014; 28(1):85-97. PMC: 3894416. DOI: 10.1101/gad.232082.113. View

Zhao X, Petrashen A, Sanders J, Peterson A, Sedivy J . SLC1A5 glutamine transporter is a target of MYC and mediates reduced mTORC1 signaling and increased fatty acid oxidation in long-lived Myc hypomorphic mice. Aging Cell. 2019; 18(3):e12947. PMC: 6516164. DOI: 10.1111/acel.12947. View

Mukhopadhyay S, Goswami D, Adiseshaiah P, Burgan W, Yi M, Guerin T . Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers. Cancer Res. 2020; 80(8):1630-1643. PMC: 7185043. DOI: 10.1158/0008-5472.CAN-19-1363. View

Sun L, Song L, Wan Q, Wu G, Li X, Wang Y . cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions. Cell Res. 2015; 25(4):429-44. PMC: 4387561. DOI: 10.1038/cr.2015.33. View

Anderton B, Camarda R, Balakrishnan S, Balakrishnan A, Kohnz R, Lim L . MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer. EMBO Rep. 2017; 18(4):569-585. PMC: 5376764. DOI: 10.15252/embr.201643068. View

Fogal V, Babic I, Chao Y, Pastorino S, Mukthavaram R, Jiang P . Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction. Oncotarget. 2014; 6(2):1157-70. PMC: 4359224. DOI: 10.18632/oncotarget.2708. View

Cadoret A, Ovejero C, Terris B, Souil E, Levy L, Lamers W . New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene. 2002; 21(54):8293-301. DOI: 10.1038/sj.onc.1206118. View

10.

Owen O, Kalhan S, Hanson R . The key role of anaplerosis and cataplerosis for citric acid cycle function. J Biol Chem. 2002; 277(34):30409-12. DOI: 10.1074/jbc.R200006200. View

11.

Le Grand M, Mukha A, Puschel J, Valli E, Kamili A, Vittorio O . Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation. Theranostics. 2020; 10(14):6411-6429. PMC: 7255021. DOI: 10.7150/thno.42602. View

12.

Nau M, Brooks B, Battey J, Sausville E, Gazdar A, Kirsch I . L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature. 1985; 318(6041):69-73. DOI: 10.1038/318069a0. View

13.

Effenberger M, Bommert K, Kunz V, Kruk J, Leich E, Rudelius M . Glutaminase inhibition in multiple myeloma induces apoptosis MYC degradation. Oncotarget. 2017; 8(49):85858-85867. PMC: 5689652. DOI: 10.18632/oncotarget.20691. View

14.

Mukhopadhyay S, Vander Heiden M, McCormick F . The Metabolic Landscape of RAS-Driven Cancers from biology to therapy. Nat Cancer. 2021; 2(3):271-283. PMC: 8045781. DOI: 10.1038/s43018-021-00184-x. View

15.

Shibutani S, Okazaki H, Iwata H . Dynamin-dependent amino acid endocytosis activates mechanistic target of rapamycin complex 1 (mTORC1). J Biol Chem. 2017; 292(44):18052-18061. PMC: 5672031. DOI: 10.1074/jbc.M117.776443. View

16.

Koppula P, Zhang Y, Zhuang L, Gan B . Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun (Lond). 2018; 38(1):12. PMC: 5993148. DOI: 10.1186/s40880-018-0288-x. View

17.

Watford M . Hepatic glutaminase expression: relationship to kidney-type glutaminase and to the urea cycle. FASEB J. 1993; 7(15):1468-74. DOI: 10.1096/fasebj.7.15.8262331. View

18.

Rabanal-Ruiz Y, Otten E, Korolchuk V . mTORC1 as the main gateway to autophagy. Essays Biochem. 2017; 61(6):565-584. PMC: 5869864. DOI: 10.1042/EBC20170027. View

19.

Josse L, Xie J, Proud C, Smales C . mTORC1 signalling and eIF4E/4E-BP1 translation initiation factor stoichiometry influence recombinant protein productivity from GS-CHOK1 cells. Biochem J. 2016; 473(24):4651-4664. PMC: 5147049. DOI: 10.1042/BCJ20160845. View

20.

Wasylishen A, Penn L . Myc: the beauty and the beast. Genes Cancer. 2011; 1(6):532-41. PMC: 3092215. DOI: 10.1177/1947601910378024. View